IMR Press / EJGO / Volume 40 / Issue 1 / DOI: 10.12892/ejgo4407.2019
Open Access Original Research
Expression of FOXA1 in breast cancer and the significance
Show Less
1 Department of General surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China
2 Department of Endoscopy center, The First Affiliated Hospital of Jinan University, Guangzhou, China

Co-first authors

Eur. J. Gynaecol. Oncol. 2019 , 40(1), 97–100; https://doi.org/10.12892/ejgo4407.2019
Published: 10 February 2019
Abstract

Objective: The aim of this study to examine the expression of FOXA1, ER, and PR in breast cancer and investigate the association between FOXA1 expression and clinical parameters. Materials and Methods: One hundred one cases with primary breast cancer were collected and immunohistochemistry was employed to examine the expression of FOXA1, ER, and PR. The correlation of FOXA1 and ER, PR expression with menopausal status, tumor size, clinical stage, histological grade, recurrence, and clinical index relationship was further analyzed. Results: The positive expression of FOXA1 was 67.3%. The positive expression rate of ER in positive FOXA1 group was 66.2% (45/68). The positive expression rate of PR in positive FOXA group was 57.4% (39/68). There was no correlation between FOXA1 expression and menopausal status. Analysis of the relationship between FOXA1 and tumor diameter showed that the percentage of tumor diameter ≤ 2 cm, 2-5 cm, and > 5 cm was 52.9%, 32.4%, and 14.7% in positive FOXA1 group. The correlation with clinical staging showed that the percentage of Stages I, II, and III was 33.8%, 41.2% and 25%, respectively, in positive FOXA1 group. Analysis of histological grade showed that the percentage of grades 1, 2, and 3 was 48.5%, 20.6%, and 23.5%, respectively, in positive FOXA1 group. The positive expression rate of P53 was 30.9%, the recurrence rate was 14.7%, and the positive expression of FOXA1 had better DFS.

Keywords
Breast cancer
FOXA1
ER
PR
Immunohistochemistry
Figures
Figure 1.
Share
Back to top